Business Description
Lyra Therapeutics Inc
NAICS : 325411
SIC : 2833
ISIN : US55234L2043
Share Class Description:
LYRA: Ordinary SharesTotal Employee Number:
27Description
Lyra Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of anti-inflammatory therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. Its products include LYR-210 and LYR-220. The company operates in a single operating segment, which is the business of developing targeted medicines to address ear, nose, and throat, or ENT, diseases.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.53 | |||||
Equity-to-Asset | -0.3 | |||||
Debt-to-Equity | -2.82 | |||||
Debt-to-EBITDA | -1.04 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -19.21 | |||||
Beneish M-Score | -3.17 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -51.6 | |||||
3-Year EBITDA Growth Rate | 40.5 | |||||
3-Year EPS without NRI Growth Rate | 41.8 | |||||
3-Year FCF Growth Rate | 36.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 36.56 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 413.6 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 49.18 | |||||
9-Day RSI | 45.76 | |||||
14-Day RSI | 45.08 | |||||
3-1 Month Momentum % | -1.52 | |||||
6-1 Month Momentum % | -66.58 | |||||
12-1 Month Momentum % | -92.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.71 | |||||
Quick Ratio | 1.71 | |||||
Cash Ratio | 1.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -40.7 | |||||
Shareholder Yield % | -82.44 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -7425.38 | |||||
Net Margin % | -7266.08 | |||||
EBITDA Margin % | -7310.05 | |||||
FCF Margin % | -7251.01 | |||||
OCF Margin % | -7251.01 | |||||
ROE % | -7077.58 | |||||
ROA % | -56.69 | |||||
ROIC % | -98.49 | |||||
3-Year ROIIC % | 183.59 | |||||
ROC (Joel Greenblatt) % | -151.08 | |||||
ROCE % | -73.59 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.78 | |||||
EV-to-EBIT | -0.52 | |||||
EV-to-EBITDA | -0.53 | |||||
EV-to-Revenue | 38.42 | |||||
EV-to-Forward-Revenue | 22.54 | |||||
EV-to-FCF | -0.53 | |||||
Price-to-GF-Value | 0.21 | |||||
Earnings Yield (Greenblatt) % | -192.31 | |||||
FCF Yield % | -3119.89 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:LYRA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lyra Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.398 | ||
| EPS (TTM) ($) | -19.16 | ||
| Beta | 2.5478 | ||
| 3-Year Sharpe Ratio | -0.79 | ||
| 3-Year Sortino Ratio | -0.99 | ||
| Volatility % | 92.06 | ||
| 14-Day RSI | 45.08 | ||
| 14-Day ATR ($) | 0.099245 | ||
| 20-Day SMA ($) | 0.592511 | ||
| 12-1 Month Momentum % | -92.33 | ||
| 52-Week Range ($) | 0.31 - 8.7478 | ||
| Shares Outstanding (Mil) | 1.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lyra Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lyra Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 119 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 27 days | ||
| General meeting for 2026 | 2026-07-23 08:00 | In 8 days | ||
| First quarter earnings results for 2026 | 2026-07-16 | 0.37 (-36.02%) | ||
| Annual report for 2025 | 2026-03-31 | 0.49 (-23.41%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 4.24 (-3.20%) | ||
| Second quarter earnings results for 2025 | 2025-08-12 | 6.67 (+1.06%) | ||
| 0.02:1 Stock Split | 2025-05-28 | 4.39 (-0.23%) | ||
| General meeting for 2025 | 2025-05-14 08:00 | 4.72 (+1.83%) | ||
| First quarter earnings results for 2025 | 2025-05-07 | 5.10 (-1.73%) |
Show
Entries
Lyra Therapeutics Inc Frequently Asked Questions
What is Lyra Therapeutics Inc(LYRA)'s stock price today?
The current price of LYRA is $0.52. The 52 week high of LYRA is $8.75 and 52 week low is $0.31.
When is next earnings date of Lyra Therapeutics Inc(LYRA)?
The next earnings date of Lyra Therapeutics Inc(LYRA) is 2026-07-16 Est..
Does Lyra Therapeutics Inc(LYRA) pay dividends? If so, how much?
Lyra Therapeutics Inc(LYRA) does not pay dividend.
Guru Commentaries on OTCPK:LYRA
No articles.
Press Release
Articles on Lyra Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers